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Abstract: Oxidative stress has been implicated in pathophysiology of different human stress- and
age-associated disorders, including osteoporosis for which antioxidants could be considered as
therapeutic remedies as was suggested recently. The 1,4-dihydropyridine (DHP) derivatives are
known for their pleiotropic activity, with some also acting as antioxidants. To find compounds with
potential antioxidative activity, a group of 27 structurally diverse DHPs, as well as one pyridine
compound, were studied. A group of 11 DHPs with 10-fold higher antioxidative potential than of uric
acid, were further tested in cell model of human osteoblast-like cells. Short-term combined effects of
DHPs and 50 µM H2O2 (1-h each), revealed better antioxidative potential of DHPs if administered
before a stressor. Indirect 24-h effect of DHPs was evaluated in cells further exposed to mild oxidative
stress conditions induced either by H2O2 or tert-butyl hydroperoxide (both 50 µM). Cell growth
(viability and proliferation), generation of ROS and intracellular glutathione concentration were
evaluated. The promotion of cell growth was highly dependent on the concentrations of DHPs used,
type of stressor applied and treatment set-up. Thiocarbatone III-1, E2-134-1 III-4, Carbatone II-1,
AV-153 IV-1, and Diethone I could be considered as therapeutic agents for osteoporosis although
further research is needed to elucidate their bioactivity mechanisms, in particular in respect to
signaling pathways involving 4-hydroxynoneal and related second messengers of free radicals.
Keywords: 1,4-dihydropyridine(s) (DHPs); oxidative stress; reactive oxygen species (ROS);
antioxidant (AO); antioxidative activity (AOA); glutathione; cell viability and proliferation;
4-hydroxynonenal (4-HNE)
1. Introduction
Oxidative stress, defined as an imbalance between pro-oxidants and antioxidants in the favor
of the former [1], has been implicated in the pathogenesis of numerous stress- and age-associated
diseases, whether as a cause or as a consequence of respective illness progression [2]. The consensus
among researchers in this field highlights the need of its better understanding as well as balancing
oxidative homeostasis to the levels that promote health [3]. Indeed, antioxidants per se or drugs
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with antioxidative properties are important for reducing the detrimental levels of reactive oxygen
species (ROS). Yet, the importance of ROS-related redox signaling in normal cellular maintenance
should not be neglected, nor the fact that antioxidative and/or pro-oxidative activity are in the
background of (un)desirable activities of many drugs and physiologically active compounds [3–5].
Thus, studies revealing bioactivities of natural antioxidants are complemented by scientific efforts
aiming to synthetize new bioactive substances with antioxidant features that could help maintaining
oxidative homeostasis of the living cells.
1,4-Dihydropyridine derivatives (DHPs) are a group of pleiotropic physiologically active
compounds (reviewed in Swarnalatha et al. [6] and Velena et al. [7]), among which many 4-nitrophenyl-
and differently substituted DHPs are known as effective antihypertensive agents. While condensed
DHPs were suggested as agents that affect stem cell differentiation [8], several DHPs exert anti- or
pro-oxidant effects in various systems both in vitro as well as in vivo [7,9].
Our present article extends the knowledge about antioxidative and potentially pro-oxidative
activities of the well-known, water-insoluble antioxidant Diethone I (also known as Dietone, Diludine,
Hantzsch ester, HEH) [7], in comparison to the water-soluble antimutagenic [10] and antimetastatic [11]
compound Carbatone (disodium-2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate)) II-1,
which prevents DNA lesions [12–15]. Moreover, comparison was done also with their analogues and
with novel DHPs (see Table 1, compounds mentioned as MM) and their derivatives.
Therefore, a set of 27 structurally diverse (of monocyclic as well as of condensed ring structures,
having symmetric as well as asymmetric alkyl-, alkoxyalkyl-, aryl-, aralkyl- or heteryl- substituents on
positions 2, 3, 4, 5 and 6) synthetic 1,4-dihydropyridine compounds (as well as for comparison one
pyridine type compound, an analogue (oxidized form) of diamide analogue J-12-25 V) (see Table 1
below) of which 14 are water soluble DHP compounds (including antimutagenic, DNA protecting,
antimetastatic, antiischaemic) and 14 are water-insoluble (more lipid soluble): 13 DHP compounds
(including antioxidant and radioprotector Hantzsch ester Diethone (Dietone) I) and one pyridine
analogue were studied.
While possibly beneficial effects of antioxidants are mostly considered for patients suffering
from malignant, cardiovascular, neurodegenerative and inflammatory diseases, osteoporosis is
an age-related disease characterized by bone loss due to the impaired bone formation and increased
bone resorption, which is less often considered as an oxidative stress-associated disease. However,
requests for treatment strategies of this chronic disease that would promote bone formation [16] also
point to oxidative stress as an important factor in pathogenesis of osteoporosis [17,18], consequently
highlighting antioxidants as important factors for prevention and treatment of osteoporosis [17,19].
Therefore, in our study, we used human osteoblast-like cells (HOS cell line) which are well known
as a model of human osteoblasts [20–22] aiming to reveal DHPs that can act as antioxidant(s) in cell-free
systems (Total antioxidative capacity (TAC) and Total oxidative capacity (TOC) assays, respectively)
but could also affect viability and growth of HOS cells under mild oxidative stress induced by two
different stressors (hydrogen peroxide and tert-butyl hydroperoxide).
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Table 1. Chemical structures and solubility of 27 1,4-dihydropyridine derivatives and one pyridine
analogue investigated in this study.
Compounds Trivial Name R3 R4 R5 Solubility Reference
I Diethone Ethanol with10% DMSO [23]
II-1 Carbatone ONa H OCH2COONa Water [24]
II-2 J-9-133-2 ONa H OCH3 Water [25]
II-3 J-9-46 OCH2CH3 H OCH2CH3 Ethanol [25]
II-4 Metcarbatone ONa CH3 OCH2COONa Water [26]
II-5 Etcarbatone ONa CH2CH3 OCH2COONa Water [26]
II-6 J-9-117(Styrylcarbatone) ONa CH=CHPh OCH2COONa Water *MM
III-1 Thiocarbatone ONa H SCH2COONa Water MM
III-2 TK-2 OCH3 H SCH2COOCH3
Ethanol with
10% DMSO MM
III-3 E-170-4 (TK-1) OCH2CH3 H SCH2COOCH2CH3
Ethanol with
10% DMSO MM
III-4 E2-134-1 ONa H OCH2CH3 Water MM
III-5 E2-135 OCH2CH3 H OCH2CH3 Ethanol MM
III-6 E2-136-2 ONa H OCH2COONa Water MM
III-7 E2-131 ONa CH2CH3 OCH2CH3 Water MM
III-8 E2-130-3 OCH2CH3 CH2CH3 OCH2CH3 Ethanol MM
III-9 E2-120 (ETK-2) OCH3 CH2CH3 SCH2COOCH3 Ethanol MM
III-10 E2-113 (ETK-1) OCH2CH3 CH2CH3 SCH2COOCH2CH3 Ethanol MM
III-11 E-163-1 ONa 3-Py OCH2CH3 Water MM
III-12 E-163-K OCH2CH3 3-Py OCH2CH3 Ethanol MM
IV-1 AV-153 OCH2CH3 ONa OCH2CH3 Water [27]
IV-2 EE-126 OCH3 ONa OCH3 Water MM
IV-3 E3-46 OCH2CH3 OH OCH2COOCH2CH3 Ethanol MM
IV-4 V-6-55-1 OCH2COOCH2CH3 OH OCH2COOCH2CH3 Ethanol MM
IV-5 AV-154-Na CH3 ONa CH3 Water [27]
IV-6 J-11-61B CH3 OH OCH2CH3 Ethanol MM
IV-7 J-11-71-2 OCH2CH3 OH Ethanol MM
IV-8 Glutapyrone OCH2CH3
NHCH(CH2)2COONa
|COONa OCH2CH3 Water [28]
V J-12-25 Ethanol MM
*MM—see in Materials and Methods. DMSO (Dimethyl sulfoxide).
2. Materials and Methods
2.1. Compounds
The studied 27 DHP compounds belong to several (five, I–V, see Table 1) relative types. All tested
DHPs were synthesized at the Latvian Institute of Organic Synthesis [24–30]. Already described
compounds are referenced in Table 1; new compounds have been synthesized by making use of
methods indicated below for each type and indexed as MM (*MM) in Table 1.
Dietone I is the basic most studied compound, all studied types are its derivatives. It could
be used as standard. It has been elaborated and developed, used as radioprotector, antioxidant
to preserve carotene, vitamins A and E, growth stimulant. Dietone I was synthesized according
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to modified Hantzsch syntesis: heterocyclization of acetoacetic ester and urotropine [23]. Type II
compounds (II-1–II-6) or Carbatone II-1 and its derivatives were prepared by making use of 1 or 2
equivalents of ethoxycarbonylmethyl ester of acetoacetic acid instead of or as addition to acetoacetic
ester. For synthesis of soluble in water salts mild hydrolysis of distant ester group was performed.
Compounds (II-1–II-6) were obtained according to procedure described in patents [24–26]. Type III
compounds (III-1–III-12) or Thiocarbatone III-1 and its derivatives were prepared by making use of
one or two equivalents of ethoxycarbonylmethyl ester of acetothioacetic acid instead of or as addition
to acetoacetic ester. Again, for synthesis of soluble in water salts mild hydrolysis of distant ester group
was performed. Compounds (III-1–III-12) were obtained following the reported method [26].
Type IV compounds (derivatives of 1,4-dihydroisonicotinic acid IV-1–IV-8) were synthesized by
making use of glyoxylic acid or its ester as aldehyde part, ethyl or methyl ester of acetoacetic acid
(and/or additionally ethoxycarbonylmethyl ester of acetylacetic acid) and ammonia. AV-153 (IV-1)
can be as intermediate for synthesis of Glutapyrone (IV-8) [28]. Compounds (MM, IV-1–IV-6) were
obtained according to procedure described in [27]. Pyridine derivative J-12-25 (V) was obtained via
oxidation of related DHP with sodium nitrite in acetic acid.
Major features of the substances tested are presented in Table 1.
Fresh stock solutions of DHPs were prepared in adequate solvent (listed in Table 1) in
a concentration of 10 mg/mL prior to each experiment.
2.2. Total Antioxidative Capacity (TAC) Assay
The total antioxidative capacity assay relying on the ability of tested compounds to scavenge
hydrogen peroxide, thus, competing with peroxidase and preventing oxidation of a chromogenic
substrate tetramethylbenzidine (TMB), was performed as previously described [31], with a slight
modification as described. The scavenging ability of DHP compounds was compared to ranging
concentration of uric acid serving as standard antioxidant. Briefly, 25 µL of a standard (uric acid serial
dilutions from 0–12 mM) or a sample (27 DHPs, as well one pyridine type compound) each 10 mg/mL)
were pipetted into each well of the 96-well microplate and mixed with 100 µL Reagent A (0.1 M citric
buffer containing 0.03% (v/v) hydrogen-peroxide). The first absorbance was measured at 450 nm
(Multiscan Ex, Thermo Electron Corporation, Shanghai, China) followed by the addition of 50 µL
Reagent B containing 1.25 mU horse radish peroxidase (HRP; Sigma Aldrich, St. Louis, MO, USA) and
0.416 mM TMB (Sigma Aldrich, St. Louis, MO, USA) in citric buffer. After 15-min incubation time,
reaction was stopped with 2 M H2SO4 and the second absorbance was measured at 450 nm (Multiscan
Ex, Thermo Electron Corporation, Shanghai, China). The difference between the second and the first
absorbance values of the tested compounds was interpolated from the uric acid standard curve and
results are presented as mM Uric acid equivalent.
2.3. Total Oxidative Capacity (TOC) Assay
A total oxidative capacity assay was performed as previously described [32]. The assay determines
peroxides present in the sample by their reaction with peroxidase followed by a color reaction with
chromogenic substrate TMB. Quantification is achieved by serial dilutions of a standard hydrogen
peroxide solution. Briefly, 10 µL of a standard (hydrogen peroxide serial dilutions from 0–0.9791 mM)
or a sample (27 DHPs, as well one pyridine type compound) was pipetted into each well of the
96-well microplate, mixed with 200 µL of reaction mixture (25 mU HRP, TMB, and substrate buffer
in a proportion of 1:10:100 (v:v:v)) and initial absorbance at 450 nm was measured (Multiscan Ex,
Thermo Electron Corporation, Shanghai, China). Plate was further incubated for 20 min and the
second absorbance at 450 nm was measured after stopping the reaction with 2 M H2SO4. The results
are expressed as µM H2O2 hydrogen peroxide equivalent.
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2.4. Cell Culture and Treatments
The human osteosarcoma cell line HOS (ATCC® CRL-1543™), purchased from the American Type
Culture Collection (ATCC, LGC Standards GmbH, Wesel, Germany) was used as an osteoblast model
to test possible the in vitro effects of selected compounds. The cells were cultivated in T75 cell culture
flasks (TPP, Trasadingen, Switzerland) in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10%
(v/v) fetal calf serum (FCS) at 37 ◦C in humidified atmosphere with 5% CO2. Prior to experiments, cells
were harvested with 0.25% (w/v) Trypsin-0.53 mM EDTA (Ethylenediaminetetraacetic acid) solution
and counted with Trypan Blue Exclusion Assay in Bürker-Türk hemocytometer (Brand, Wertheim,
Germany). Thus prepared cells were seeded at a density of 2 × 104 cells/well into 96-microwell plates
(TPP, Trasadingen, Switzerland) and left for 24 h to attach. Afterwards, we evaluated the potential
of selected compounds to influence intracellular ROS production upon administration of hydrogen
peroxide. Cell cultures were either first exposed to 50 µM hydrogen peroxide for one hour before
addition of selected compounds (100 or 1000 µM) or vice versa. The immediate effect on cellular
viability was also evaluated in case of cells that were first exposed to selected compounds for one hour,
followed by one-hour incubation with hydrogen peroxide, aiming to test possible beneficial effects of
the tested substances that might prevent the onset of the cellular oxidative stress.
The second series of experiments were conducted with prolonged (24-h) exposure of cells to
selected compounds before one-hour exposure to hydrogen-peroxide. The experiments are explained
in more details in the following subsections.
2.5. Cellular Viability (Tetrazolium Reduction Assay)
Viability (metabolic activity) of the cultured HOS cells was evaluated with the EZ4U assay
(Biomedica, Wien, Austria) according to manufacturer’s instructions. The assay principle is based on
reduction of tetrazolium salts to colored formazan derivatives by living cells, the intensity of which is
measured spectrophotometrically as proportional to the number of viable cells in the culture sample.
Cells seeded at a density of 2 × 104 cells/well in 96-microwell plates (TPP, Trasadingen,
Switzerland) were left to attach for 24 h prior to treatments. For the short-term treatment, cells
were first treated with selected compounds (100 µM and 1000 µM concentration; except for Diethone I
for which only 100 µM concentration was used because it precipitates at 1000 µM) for 1 h, after which
hydrogen peroxide was added for an additional hour. In case of experiments with longer exposure
to selected compounds, HOS cells were treated with different concentrations of selected compounds
(ranging from 10 µM to 1000 µM, depending on the compound used) and left for additional 24 h,
followed by the change of cell culture medium. Cellular viability was determined for cell culture either
treated just by selected compounds or for those additionally treated with 50 µM hydrogen peroxide
or with 50 µM tert-butyl hydroperoxide (tBHP; Sigma Aldrich, St. Louis, MO, USA) for one-hour,
respectively. Afterwards, the medium was replaced with 200 µL Hanks’ solution (pH 7.4) and 20 µL of
dye solution was added to each well followed by two-hour incubation at 37 ◦C. The absorbance was
measured at 450 nm with a reference wavelength of 620 nm using a microplate reader (Multiscan Ex,
Thermo Electron Corporation, Shanghai, China). Thus obtained results were expressed as percentage
of non-treated control.
2.6. Cell Proliferation (BrdU Assay)
Cell proliferation was determined in the experiments where cells were exposed to selected DHP
compounds for 24-h used alone or in combination with 50 µM hydrogen peroxide or tBHP, as described
in the previous section. The 5-bromo-2′-deoxyuridine (BrdU) colorimetric assay (Roche Applied
Science, Mannheim, Germany) was used, according to the manufacturer’s instruction. The assay
relies on the ability of the BrdU to incorporate into cellular DNA during proliferation which is further
detected by an anti-BrdU antibody. Briefly, after specified time points of treatments (24-h treatment with
the compound alone or followed by 1-h treatment with hydrogen peroxide and tBHP), the BrdU was
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added to each well and left for two-hours at 37 ◦C. The culture medium was removed and the cells were
washed twice with Hanks’ solution before fixation with FixDenat solution for 30 min. Subsequently,
the anti-BrdU-peroxidase (1:100) was added to each well and incubated at room temperature for 90 min.
After removing the unbound antibody conjugate, 100 µL of the substrate solution was added and
allowed to stand for 15 min. The reaction was quenched by adding 25 µL of a 1 M H2SO4 solution.
The absorbance was measured at 450 nm with a reference wavelength of 620 nm using a microplate
reader (Multiscan Ex, Thermo Electron Corporation, Shanghai, China).The results are presented as
percentage of non-treated control.
2.7. Measurement of intracellular ROS production
The ROS measurement is based on the intracellular oxidation of 2′,7′-dichlorodihydrofluorescein
diacetate (DCFH-DA; Sigma-Aldrich, St. Louis, MO, USA) to a fluorescent 2′,7′-dichlorofluorescein
(DCF) that can be measured. Intracellular ROS levels were measured upon short-term (1-h) treatment
and after 24-h treatment with selected DHPs, described hereafter. For all experiments, HOS cells were
seeded at the density of 2 × 104 cells/well into white 96-microwell plates (Thermo Fisher Scientific,
Nunc A/S, Roskilde, Denmark) and left for 24 h to attach.
In the short-term treatment, time-dependent ROS production was measured in cells treated
at specific time points as follows: (a) hydrogen peroxide 1-h + DHPs, or (b) DHPs 1-h + hydrogen
peroxide. Cells were first incubated with 10 µM DCFH-DA at 37 ◦C for 30 min, followed by fresh media
exchange and a zero-point ROS measurement with a Cary Eclipse Fluorescence Spectrophotometer
(Varian Australia Pty Ltd, Mulgrave, Victoria, Australia) with excitation at 500 nm and emission
detection at 530 nm. Treatments were carried out with 1000 µM concentration of DHPs (exception
Diethone I used as 100 µM because it precipitates at 1000 µM) and 50 µM hydrogen peroxide without
the medium change. Further fluorescence measurements were done: immediately after addition of the
first treatment (5-min point), 30- and 60-min points, immediately after addition of the second treatment
(65-min point) and up to four hours afterwards (90-, 120-, 180-, and 240-min points). The results are
expressed as relative fluorescence units (RFU) measured at specified time points.
Intracellular ROS production was also evaluated upon 24-h treatment with selected DHPs.
Following 24-h treatment, media was replaced with the Hanks’ solution containing 10 µM DCFH-DA
and cells were further incubated for 30 min on 37 ◦C. Next, the medium was replaced with the fresh
one and fluorescence was measured prior to the addition of 50 µM tBHP (zero-point) and after 1-h.
Measurements were carried with a Cary Eclipse Fluorescence Spectrophotometer (Varian Australia
Pty Ltd, Mulgrave, Victoria, Australia) as previously stated. Cells were further trypsinized with
0.25% (w/v) Trypsin-0.53 mM EDTA solution and counted with Trypan Blue Exclusion Assay in
a Bürker–Türk hemocytometer (Brand, Wertheim, Germany). The results are expressed in arbitrary
units which are a ratio of the difference in fluorescence (1-h point–zero-point) and cell number.
2.8. Determination of Glutathione (GSH) Levels
Cells were first trypsinized (0.25% (w/v) Trypsin-0.53 mM EDTA solution), washed twice with
phosphate-buffer saline (PBS) and stored as dry pellets at −80 ◦C until analysis. Cell lysates were
obtained by addition of 100 µL PBS and repeated thaw-freeze cycles, followed by centrifugation at
16,000× g/15 min. and collection of a supernatant containing proteins. Protein concentration in each
sample was determined according to Bradford method [33], using bovine serum albumin as a standard.
The total intracellular GSH content (oxidized and reduced) was measured as previously
described [34]. Briefly, 150 µL of each sample, containing 0.03 mg/mL of protein, or standard,
reduced glutathione in serial dilutions (0–20 mg/mL) was pipetted into each well of 96-microwell
plate. Reaction was started by addition of freshly prepared reaction mixture: 1.8 mM
5,5-dithio-bis-2-nitrobenzoic acid, 0.4 U GSH reductase, and 0.6 mM NADPH in phosphate buffer
(100 mM NaH2PO4, 5 mM EDTA pH 7.4). The formation of 2-nitro-5-thiobenzoic acid was monitored
spectrophotometrically in a plate reader at 405 nm (Multiscan Ex, Thermo Electron Corporation,
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Shanghai, China). Total GSH concentration in cell lysates was calculated from the standard curve by
linear regression and expressed as µM of total GSH.
2.9. Statistical Analysis
Cell-free colorimetric assays (TAC and TOC) were conducted in duplicates while cell-based
methods (EZ4U assay, BrdU assay, ROS and GSH measurements) were carried out in at least triplicates.
The respective numbers of biological replicates (n) is given in each figure legend. Data are expressed
as mean values with standard deviations. Results were analyzed with Student’s t-test and values of
p < 0.05 were considered as statistically significant.
3. Results
3.1. Total Antioxidative Capacity
The results of the total antioxidative capacity assay for tested DHPs are listed in Table 2.
In comparison to uric acid, used as a standard, the following compounds (at 1 mM concentration) were
more effective: Diethone I, J-9-133-2 II-2, AV-153 IV-1, AV-154-Na IV-5, J-11-71-2 IV-7, Carbatone II-1,
Thiocarbatone III-1, E-2-134-1 III-4, E-2-136-2 III-6, V-6-55-1 IV-4, and E-3-46 IV-3 (about 10-fold or
more); J-11-61B IV-6 (8-fold); J-9-46 II-3 and E-2-135 III-5 (2-fold). J-9-117 II-6 and E2-130-3 III-8 were
as effective as uric acid while other tested compounds did not have pronounced antioxidative potential.
Accordingly, the DHPs with pronounced antioxidative capacities were selected for the treatment of
human osteoblast-like cells (HOS).
Table 2. Total antioxidant capacity of selected compounds expressed as equivalent to mM uric acid.
Compounds Trivial Name
Concentrations Tested
10 µM 100 µM 1000 µM
Equivalent to mM Uric Acid
I Diethone 1.463 ± 1.016 1.465 ± 0.085 >10
II-1 Carbatone 0.438 ± 0.177 1.534 ± 0.064 9.692 ± 0.036
II-2 J-9-133-2 0.585 ± 0.074 3.756 ± 0.312 >10
II-3 J-9-46 0 0.148 ± 0.088 2.284 ± 0.504
II-4 Metcarbatone 0 0.526 ± 0.033 0.852 ± 0.013
II-5 Etcarbatone 0.027 ± 0.038 0.057 ± 0.019 0.206 ± 0.085
II-6 J-9-117(Styrylcarbatone) 0.680 ± 0.051 0.421 ± 0.596 1.073 ± 0.04
III-1 Thiocarbatone 1.279 ± 0.046 2.735 ± 0.363 >10
III-2 TK-2 0 0 0
III-3 E-170-4 (TK-1) 0 0 0
III-4 E2-134-1 0.770 ± 0.075 0.541 ± 0.304 >10
III-5 E2-135 0.027 ± 0.302 0.564 ± 0.422 1.968 ± 0.294
III-6 E2-136-2 0.498 ± 0.115 1.082 ± 0.175 >10
III-7 E2-131 0.778 ± 0.085 0 0
III-8 E2-130-3 0.355 ± 0.234 0.285 ± 0.398 0.980 ± 0.129
III-9 E2-120 (ETK-2) 0 0.042 ± 0.007 0
III-10 E2-113 (ETK-1) 0.032 ± 0.195 0.077 ± 0.219 0
III-11 E-163-1 0 0 0
III-12 E-163-K 0 0 0
IV-1 AV-153 0.153 ± 0.216 2.005 ± 0.053 9.828 ± 0.081
IV-2 EE-126 0.856 ± 0.614 0.304 ± 0.078 0.292 ± 0.083
IV-3 E3-46 0.075 ± 0.163 1.542 ± 0.120 >10
IV-4 V-6-55-1 0.636 ± 0.220 4.013 ± 0.228 >10
IV-5 AV-154-Na 0.481 ± 0.028 2.774 ± 0.199 >10
IV-6 J-11-61B 0 0.948 ± 0.056 8.222 ± 0
IV-7 J-11-71-2 0 3.160 ± 0.094 >10
IV-8 Glutapyrone 0.190 ± 0.015 0.127 ± 0.096 0
V J-12-25 0.016 ± 0.193 0.050 ± 0.040 0.012 ± 0.044
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3.2. Total Oxidative Capacity
The results of the total oxidative capacity assay are listed in Table 3. Oxidative potential of the
majority of the tested DHPs was either absent or, if present, not proportional to the concentration used.
AV-153 IV-1, Carbatone II-1 and E-170-4 III-3 (TK1 III-3) were the only compounds showing oxidative
potential somewhat proportional to the concentration used. While pro-oxidative activity of E-170-4
III-3 (TK-1 III-3) was very low, but proportional to the concentration range, mild oxidative potential
of lower concentrations (10 µM and 100 µM) and negligible of the highest (1000 µM) was observed
for AV-153 IV-1 and Carbatone II-1. Still, it was about 2-fold (AV-153 IV-1) and 5-fold (Carbatone II-1)
lower than of hydrogen peroxide.
Table 3. The oxidative capacity of selected compounds expressed as equivalent to µM H2O2.
Compounds Trivial Name
Concentrations Tested
10 µM 100 µM 1000 µM
Equivalent to µM H2O2
I Diethone 1.346 ± 1.904 0 0
II-1 Carbatone 2.692 ± 0.000 18.846 ± 1.088 1.538 ± 0.544
II-2 J-9-133-2 0.250 ± 0.374 0 0
II-3 J-9-46 0 0 0
II-4 Metcarbatone 0 0 0
II-5 Etcarbatone 0 0 0
II-6 J-9-117(Styrylcarbatone) 0.577 ± 0.816 0 0.192 ± 0.272
III-1 Thiocarbatone 0 0 0
III-2 TK-2 0 0 7.558 ± 1.791
III-3 E-170-4 (TK-1) 0 3.375±1.768 38.529 ± 1.663
III-4 E2-134-1 0 0 0
III-5 E2-135 0 0 0
III-6 E2-136-2 0 0 0
III-7 E2-131 0 5.411 ± 1.663 6.588 ± 3.328
III-8 E2-130-3 0 0 0
III-9 E2-120 (ETK-2) 0 0 13.235 ± 5.407
III-10 E2-113 (ETK-1) 0 0 0.147±0.208
III-11 E-163-1 0 4.5 ± 1.179 13.059 ± 1.664
III-12 E-163-K 0 0 0
IV-1 AV-153 6.923 ± 0.544 41.154 ± 1.088 5.00 ± 4.351
IV-2 EE-126 3.625 ± 0.884 3.938 ± 0.442 3.938 ± 0.442
IV-3 E3-46 0 7.243 ± 0.114 0
IV-4 V-6-55-1 0.481 ± 0.680 0 0
IV-5 AV-154-Na 3.938 ± 0.442 3.625 ± 0.884 0
IV-6 J-11-61B 0 0 0
IV-7 J-11-71-2 0.938 ± 0.000 1.875 ± 0.000 0
IV-8 Glutapyrone 0 0 0
V J-12-25 0 0 0
3.3. Short-Term (1-h) Treatment of HOS Cells with DHPs and Hydrogen Peroxide
3.3.1. Measurement of Intracellular ROS Production
The ability of the tested DHPs to scavenge hydrogen peroxide revealed better reduction of
intracellular ROS levels if DHPs were applied before the addition of the stressor. Such antioxidative
effects were especially pronounced for water-soluble DHPs and Diethone I, observed as reduction of
ROS levels almost to level of non-stressed control (Figure 1A,B). The E3-46 IV-3 was not so effective,
its effects were pronounced after 120 min and were not reaching the effects of the other effective DHPs
(Figure 1B). On the other hand, if the cells were first exposed to hydrogen peroxide for one hour,
the scavenging ability of the majority of tested DHPs was not so pronounced for, still being present
(Figure 1C,D). In this type of treatment, E3-46 IV-3 was the only compound unable to reduce but even
increased ROS levels during 4-h measurement (Figure 1D). In both types of treatments, intracellular
ROS levels of control cells (without stressor) remained low during the course of 4-h measurement.
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Taken together results of both treatments (DHPs before or after stressor) revealed better
antioxidative potential of the tested DHPs given before stressor, i.e., when cells were not already
damaged by hydrogen peroxide. Moreover, ROS reduction indicated direct scavenging of hydrogen
peroxide by the tested DHPs along with possible induction of the cellular protective mechanisms
(endogenous antioxidants).
Figure 1. Intracellular ROS of HOS cells exposed to DHPs and H2O2.Cells were treated with DHPs
and hydrogen peroxide, without the exchange of culture medium, as follows: (A,B) 1-h DHPs +
hydrogen peroxide, or (C,D) 1-h hydrogen peroxide + DHPs. The fluorescence reflecting intracellular
ROS levels was measured at different time points (0—no treatment, 5—immediately after the first
treatment, 30, 60, 65—immediately after the second treatment, 90, 120, 180, 240 min). Results of DHPs
(A,C—water-soluble; B,D—soluble in organic solvents) are presented as mean of relative fluorescence
units (RFU) ± standard deviation (n = 2). Controls: ctrl (untreated cells), ctrl H2O2 (cells treated with
hydrogen peroxide) and solvent-controls (vehicle Diethone I and vehicle E3-46 IV-3).
3.3.2. Cellular Viability
The effects of selected DHPs on cellular viability (Figure 2) were analyzed for cells treated
with DHPs alone (non-stress condition) or in combination with 50 µM hydrogen peroxide
(IC30—corresponding to induction of mild oxidative stress). The E-2-134-1 III-4 (1000 µM) significantly
increased cellular viability both in case of non-stress and in mild-stress culturing conditions (p < 0.05
and p < 0.005, respectively) while for AV-153 IV-1 (1000 µM) and Thiocarbatone III-1 (1000 µM) cellular
viability was significantly increased only under mild-stress conditions (p < 0.005 and p < 0.0005,
respectively). Interestingly decreased cellular viability (metabolism) was observed by EZ4U assay
for Carbatone II-1 and J-9-133-2 II-2, which were previously (Figure 1) found to reduce ROS levels,
even below non-treated control levels.
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Therefore, evaluation of ROS production and cellular viability for short-term treatments
have accentuated Thiocarbatone III-1, AV-153 IV-1 and in particular E-2-134-1 III-4 (at 1000 µM
concentration) as likely the most potent and bioactive DHP antioxidants in the tested group due to
their beneficial growth promoting and ROS scavenging effects under mild oxidative stress conditions.
Figure 2. Cellular viability measured by EZ4U assay upon 1 h treatment with DHPs and H2O2. HOS
cells were first treated with DHPs (100 µM and 1000 µM) for one-hour, followed by one-hour treatment
with 50 µM hydrogen peroxide or with plain medium. Values are given as mean ± standard deviation;
n = 3. Statistically significant differences to their respective controls are shown as follows: * p < 0.05;
+ p < 0.005; # p < 0.0005.
3.4. The Effects of 24-h Pre-Treatment of Cells with DHPs before Exposure to Hydrogen Peroxide or
Tert-Butyl Hydroperoxide
3.4.1. Hydrogen Peroxide as a Stressor
The possible growth-promoting potential of DHPs was further evaluated in non-stress (without
addition of stressor) as well as in mild oxidative stress conditions (addition of H2O2 as stressor).
Stimulatory effects of 1000 µM AV-153 IV-1 and AV-154-Na IV-5 on cell viability (EZ4U assay, p < 0.05)
or proliferation (BrdU assay, p < 0.005), respectively, were observed. Other DHPs did not enhance but
have even inhibited cell growth, particularly 1000 µM Carbatone II-1 and J-9-133-2 II-2. Treatment
with hydrogen peroxide affected more cell proliferation than viability. Negative effect of hydrogen
peroxide was attenuated with low concentration (10 µM) of AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2,
Carbatone II-1 and Diethone I (Figure 3A,B).
The results have shown attenuation of oxidative stress-induced suppression of cell growth for
AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2, Carbatone II-1, and Diethone I (when present at low
concentrations), thus suggesting potential beneficial effects as of these DHPs as bioactive antioxidants.
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Figure 3. Cell viability (A) and proliferation (B) upon 24-h treatment with DHPs followed by 1-h
exposure to H2O2. Results are expressed as a percentage of non-treated control. Statistically significant
differences between—(a) DHPs alone vs. non-treated control (pale grey bars) or (b) DHPs treated vs.
treated control (dark grey bars) are shown as follows: a*/b* p < 0.05; a+/b+ p < 0.005; a#/b# p < 0.0005.
Values are given as mean ± standard deviation, n = 4.
3.4.2. Tert-Butyl Hydroperoxide(tBHP) as a Stressor
Cell Viability and Proliferation
Cell viability and proliferation were tested for a range of concentrations (10–1000 µM) of
AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2, Carbatone II-1, and Diethone I (five of previously tested
compounds), as well as for Thiocarbatone III-1, E2-134-1 III-4, E2-136-2 III-6, and E3-46 IV-3 (four
newly tested compounds). The majority of selected DHPs, per se, significantly stimulated cellular
viability, according to the EZ4U assay, but did not affect cell proliferation according to the BrdU assay
(Figure 4A). Hence, different concentrations of DHPs were selected for evaluation of respective DHPs’
effects on HOS cells under mild oxidative stress conditions using 50 µM tBHP as a stressor. As in case
of hydrogen peroxide, tBHP suppressed cell proliferation more than cellular viability. The E2-134-1
III-4 stimulated both, cell viability (500 µM, p < 0.05) and proliferation (250 µM, p < 0.05) while
Carbatone II-1 (250 µM; p < 0.05) and Thiocarbatone III-1 (100 µM; p < 0.05) stimulated either viability
or proliferation (Figure 4B,C).
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Figure 4. Cell viability (EZ4U assay) and proliferation (BrdU assay). (A) just DHPs without tBHP;
(B) and (C) cell cultures treated with 50 µM tBHP. Results are expressed as a percentage of non-treated
control. Values are given as mean ± standard deviation; n = 4. In comparison to the treatment control
(ctrl tBHP), statistically significant differences are shown as follows: * p < 0.05; # p < 0.0005.
Intracellular ROS Production
As expected, pro-oxidant stressor tBHP increased the production of intracellular ROS while DHPs
have shown diverse mostly concentration-dependent patterns (Figure 5). The highest reduction of ROS
was observed with 250 µM Diethone I, which was the only DHP able to decrease ROS levels even below
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that of non-treated controls (p < 0.005). The highest applied concentration (500 µM) of Thiocarbatone
III-1 and of E2-134-1 III-4, decreased ROS levels to the level of non-treated controls (p < 0.0005).
These DHPs were also effective at 250 µM (p < 0.05 and p < 0.005), while the lowest concentration
applied (100 µM) increased intracellular ROS production (p < 0.005 and p < 0.0005). The AV-153 IV-1
and AV-154-Na IV-5 have shown a concentration-dependent bell-shaped curve, whereas in general,
AV-154-Na IV-5 increased ROS levels (suggesting its pro-oxidant role), while similar pro-oxidative
effect of AV-153 IV-1 was just observed in the middle concentration range of the substance used
(250 µM; p < 0.05), to be followed by antioxidant effect of ROS reduction observed for the highest
concentration (100 µM; p < 0.05). Carbatone II-1 was effective in reducing the ROS levels at higher
concentrations (250 µM, p < 0.0005; 500 µM, p < 0.05), while E2-136-2 III-6 was effective as antioxidant
at 250 µM (p < 0.05), not affecting ROS levels in other concentrations. Finally, E3-46 IV-3 and J-9-133-2
II-2 were mostly effective as pro-oxidants, particularly E3-46 IV-3 if used at a lower concentration
range (100 µM, p < 0.05; 250 µM, p < 0.005).
Figure 5. Intracellular ROS levels upon 24-h treatment with DHPs in mild oxidative stress conditions
(1-h treatment with 50 µM t-BHP). Results are expressed in arbitrary units, adjusting the difference
in fluorescence measurement after 1-h treatment with tBHP and zero-point (before addition of tBHP)
with the cell number. Values are given as mean ± standard deviation (n = 3). Statistically significant
differences are shown as follows: * p < 0.05; + p < 0.005; # p < 0.0005 (in comparison to the treatment
control (ctrl tBHP; dotted line)); and a+ p < 0.005 (in comparison to the non-treated control (ctrl;
dashed line)).
Determination of Total Glutathione Level in the Cells
Glutathione depletion was observed in HOS cells upon tBHP treatment (Figure 6). All tested
DHPs were able to amend such tBHP-induced glutathione depletions at least in the case of some used
concentrations. The only case of additional decrease of glutathione below the levels reduced by tBHP
was observed for AV-153 IV-1 (1000 µM; p < 0.05), E2-134-1 III-4 (100 µM; p < 0.05), and J-9-133-2 II-2
(500 µM; p < 0.005). Opposite to that some of tested DHPs were able to increase glutathione above
the level of non-treated control. Such enhancing effect was observed for AV-154-Na IV-5 (1000 µM;
p < 0.05), E2-134-1 III-4 (500 µM; p < 0.05), Diethone I (100 µM; p < 0.05), Carbatone II-1 (250 µM;
p < 0.005), E3-46 IV-3 (250 µM; p < 0.05), and Thiocarbatone III-1 (100 µM; p < 0.005 and 500 µM;
p < 0.05). Surprisingly, Thiocarbatone III-1, while being able to increase glutathione more than the
other tested DHPs (100 µM; p < 0.005), if applied at 250 µM concentration this DHP did not amend the
tBHP-caused glutathione-depletion, thus producing the U-shaped concentration-dependence curve.
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The glutathione levels for other DHPs were either proportional with their increasing concentrations
(e.g., E2-134-1 III-4, E-2-136-2 III-6) or decreasing with their increasing concentrations (e.g., AV-153
IV-1, Diethone I) or forming a bell-shaped curve (e.g., Carbatone II-1, E3-46 IV-3).
Figure 6. Concentration of total glutathione in cell lysates after 24-h treatment with DHPs followed by
1-h exposure to mild oxidative stress (50 µM tBHP). Statistically significant difference between DHPs
and (a) non-treated control (ctrl (dashed line); only for the significant increase) or (b) treated control
(ctrl tBHP (dotted line)) is given as follows: a*/b* p < 0.05; a+/b+ p < 0.005 with the difference between
ctrl vs. ctrl tBHP as + p < 0.005. Values are given as mean ± standard deviation, n = 3.
In summary, the results of 24-h exposure of cells to DHPs prior the induction of mild oxidative
stress (50 µM tBHP) revealed that Thiocarbatone III-1, Carbatone II-1 and in particular E2-134-1
III-4 were the only DHPs able to promote cell growth under oxidative stress conditions, acting
in a concentration-dependent manner. While growth promotion was associated, as expected,
with reduction of ROS and induction of the intracellular glutathione for E2-134-1 III-4 (250 µM
and 500 µM) and Carbatone II-1 (250 µM), in case of the most pronounced increase of glutathione
observed for Thiocarbatone III-1 (100 µM), an increase of intracellular ROS was shown, too.
4. Discussion
The results of our study are in line with emerging evidence supporting pleiotropic, against oxidative
stress-oriented, actions of DHPs. Thus, 4-aryl-2,6-dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyridines is
already in use as novel skin-protecting agents, which inhibit elastase enzyme and protect against
ROS [35]. In addition, the antioxidative ability of DHPs was used for creating more stable,
light-sensitive DHP polythiophene derivatives (PTDHPs) as better alternatives to fluorescent probes
used for cell imaging. These PTDHPs, via DHP groups, were found to regulate angiotensin-induced
intracellular oxidative stress [36]. Recently, effective ROS radical scavenging was found also
for some mitochondria-targeting DHPs [37]. These Mito-DHPs are promising antioxidants since
they could protect both against radiation- and ROS-induced DNA strand breaks. These findings
further confirm previous data on antioxidant and reductant activities of DHPs (Diethone I and
its analogues) [38,39], pointing to mitochondria as targets for cell protective, bioactive DHP
antioxidants [40,41]. This assumption is further supported by the current study since we observed
differences in biological activities of DHPs in respect to biological parameter analyzed (cell proliferation
vs. viability), which might be due to the fact that cellular viability was analyzed by EZ4U assay that
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reflects mitochondrial dehydrogenase activities. The same stands also for the observed differential
effects of DHPs in respect to their direct pro- and anti-oxidative capacities (TOC/TAC assays based on
hydrogen peroxide/peroxidase activity principle) vs. influence of DHPs on intracellular production
of ROS, which is dependent on cellular oxidative homeostasis affecting viability and mitochondrial
stability of the cells.
This study of pro- and anti-oxidant capacities of 27 structurally different DHPs (as well as one
pyridine type compound) support previous findings, further indicating growth-regulating bioactivities
of several DHPs acting on human osteoblast-like cells. The used DHPs, roughly divided into four
subtypes comprising Diethone (Diludine) I and its analogues, Carbatone II-1 and its analogues,
Thiocartbatone (III-1) and its analogues, as well 1,4-dihydroisonicotinic acid derivatives (such as
AV-153 IV-1) and its analogues, were primarily evaluated for their antioxidative ability (TAC assay)
as well as for their potential pro-oxidative ability (TOC assay). Antioxidative potential of 1 mM
concentration of Diethone I, AV-154-Na IV-5, Thiocarbatone III-1, E2-134-1 III-4, E2-136-2 III-6,
J-9-133-2 II-2, E3-46 IV-3, J-11-71-2 IV-7, V-6-55-1 IV-4, Carbatone II-1, and AV-153 IV-1 was about
10-fold higher than was antioxidant capacity of uric acid, the well-known natural antioxidant used
as standard. There are main, node structures of DHPs possessing quite high antioxidative capacity
known for Diethone I, Carbatone II-1, AV-153 IV-1 and AV-154-Na IV-5, according to the structure:
function analysis. Extension of substituents in positions 3 and 5 of Diethone I (ethoxycarbonyl to
alkoxycarbonyl-methoxycarbonyl) and its thioderivative (E170-4, TK-2 III-2) leads to substantial
diminution of antioxidative capacity. On the contrary, compounds possessing carboxylate anions in
positions 3 (or 3 and 5) of Diethone I possess high antioxidative activity (Carbatone II-1, Thiocarbatone
III-1, also 4-carboxycarbatone V-6-55-1 IV-4, hybrids of Carbatone II-1 or Thiocarbatone III-1 and
Diethone I such as E2-134-1 III-4, J-9-133-2 II-2). Insertion of substituents in position 4 of Carbatone
II-1 (methyl, ethyl, styryl groups) diminishes antioxidative activity to the levels of uric acid for
Styrylcarbatone II-6 (J-9-117 II-6) and Metcarbatone II-4 or almost completely suppresses in case
of Etcarbatone II-5. However, a carboxylate anion in position 4 leads to the already mentioned
antioxidative activity observed for AV-153 IV-1 and AV-154-Na IV-5. Moreover, hybrids of Carbatone
II-1 ester and Diethone I possess high antioxidative capacity if compounds have 4-carboxylate
anion (V-6-55-1 IV-4 and E3-46 IV-3). If carboxylate groups in position 4 are distant from the
DHP cycle (Glutapyrone IV-8), antioxidative activity is absent. The oxidized form (pyridine type
compound J-12-25 V) was found to be inactive. Antioxidant activity mechanisms of DHPs studied
may include direct scavenging of ROS (namely, hydrogen peroxide and free radicals derived from
it) and decomposition of hydrogen peroxide in the manner, in which ROS will be produced in lesser
degree. Namely, it was observed before that Carbatone II-1 and its derivatives scavenge hydroxyl
radicals (spectrophotometric and EPR detection) produced in Fenton reaction [7,14]. Furthermore, EPR
spectroscopy showed that Metcarbatone II-4 acts as effective scavenger of hydroxyl radicals produced
in the Fenton reaction, while Etcarbatone II-5, and Propcarbatone (close analogue of Etcarbatone II-5
having propyl group instead of ethyl group) are less effective, and Styrylcarbatone II-6 is not effective
at all. In addition, DHPs affecting TAC could be converted in their heteroaromatic oxidized form [42].
Pro-oxidative potential, measured by the TOC assay (Table 3), of the majority of the tested
DHPs was either absent or minor. AV-153 IV-1, Carbatone II-1 and E-170-4 III-3 (TK1, III-3) were
the only compounds showing oxidative potential somewhat proportional to the concentration used.
While pro-oxidative activity of E-170-4 III-3 (TK-1 III-3; diethyl ester of Thiocarbatone III-1) was very
low, mild oxidative potential of lower concentrations (10 µM and 100 µM) and negligible of the highest
(1000 µM) were observed for AV-153 IV-1 and Carbatone II-1. Still, it was about 2-fold (AV-153 IV-1)
and 5-fold (Carbatone II-1) lower than of hydrogen peroxide. Therefore, the oxidative ability tested
by this assay was very moderate or absent suggesting that DHPs are less prone to oxidative activity.
Concerning TOC effects, it should be mentioned that Tirzit et al. [43] showed possibility of free-radical
reaction propagation by DHPs in vitro. If water-soluble DHPs (where R4 = H, or CH3, or COONa)
have methyl group in the 4-th position, the possibility of that compounds reactivity against hydroxyl
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radical generation is lowered. However, introduction of strong electron donor group carboxylate-ion
(COONa) causes sharp increase of reaction power. Even the introduction of carboxylate-ion in the
positions 2 and 6 of the DHP ring increased this reactivity. The generation potency was observed at
0.5 mM and 1 mM, respectively 500 µM and 1000 µM concentrations, while at higher concentrations,
the hydroxyl radical (HO•) generation is more pronounced. In addition, both assays, TAC and
TOC, use HRP (horse radish peroxidase)-catalyzed oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB)
(reduced form of this is colorless) which includes either free radical (one-electron oxidation product)
and/or charge transfer complex intermediates, both resulting in the formation of blue-colored reaction
product [44]. However, it is difficult to discriminate between a one-electron and a two-electron
mechanism for the initial enzymatic step in the reaction, thus the DHPs could react even as free
radical quenchers or propagators (by one-electron or two-electron mechanisms) of free radical chain
reactions (depending on assays used, DHPs chemical structure and concentration). Indeed, both, strong
antioxidative activity and mild oxidative potential was observed for Carbatone II-1 and AV-153 IV-1.
Moreover, as being effectors of TAC/TOC systems in the presence of HRP, 1,4-DHPs themselves could
also be enzymatically oxidized [45,46]. Thus, the elementary steps of oxidation of water-insoluble
lipophilic calcium antagonist Nifedipine (NF) catalyzed by enzyme HRP have been described by
analysis of kinetic magnetic field effects (MFEs). It has been shown that the first step of the catalytic
cycle is single electron transfer resulting in formation of NF*(+) radical cation and ferroperoxidase
(Per(2+)) [46]. As a result, comparison with an earlier studied oxidation reaction of NADH catalyzed by
HRP evidenced that the enzymatic oxidations of two substrates, native, NADH, and its synthetic DHP
analogue, NF-catalyzed by HRP in the absence of hydrogen peroxide follow identical mechanisms. It is
likely, that analogous reaction route could proceed in the case of the set of lipophilic DHPs (see Table 1)
studied here. Besides, peroxide oxidation (without peroxidase, in Fenton system a.o.) of DHPs could
occur [47].
Since previous studies have shown that various DHPs can achieve modulation of cellular
responses to oxidative stress and thus influence cell growth and differentiation [30,48], the major
aim of the current study was to find a DHP compound or a group of them that will act as potential
antioxidants and could modify the growth of human–osteoblast cells indicating their possibly beneficial
effects for treatment of osteoporosis and related bone disorders. Since oxidative stress was implicated in
pathogenesis of osteoporosis (manifested as deterioration of bone) and antioxidants, such as lycopene
and polyphenols have been suggested to benefit the therapy of osteoporosis [17,19,49], we studied
the antioxidative potential of the selected DHPs which were 10-fold more effective than uric acid on
HOS cells in mild oxidative stress conditions. Although normal human osteoblasts would be preferred
model, due to their limited availability and donor-related influences, human osteoblast-like cancer cell
lines have been widely used model systems for human osteoblasts, in particular HOS cells are known
as such in vitro model [20–22].
To evaluate short-term, cell-protective (ROS decreasing) effects of DHPs, cells were treated with
the selected DHPs and hydrogen peroxide, in general, for 1-h each. Thiocarbatone III-1, AV-153 IV-1,
E2-134-1 III-4, E2-136-2 III-6, and Diethone I decreased ROS levels showing antioxidative potential,
which was pronounced if the cells were not already damaged by hydrogen peroxide. Moreover,
observed ROS reduction indicates direct scavenging of hydrogen peroxide by the mentioned DHPs
along with possible induction of cellular-protective, antioxidant mechanisms. In addition, while
Diethone I and E2-136-2 III-6 did not affect cell growth, Thiocarbatone III-1, AV-153 IV-1 and in
particular E2-134-1 III-4 did, thus emerging as the most potent antioxidants in the tested group, able to
reduce oxidative stress-induced damage. Noteworthy, we cannot state with certainty whether the
observed beneficial effects upon short-term treatment (DHPs and hydrogen peroxide being present
in the medium at the same time for specified time-points) are just due to scavenging of hydrogen
peroxide by DHPs (which is negligible without added catalysts) or their ability to induce cellular
protective mechanism(s), or even both.
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We further explored whether DHPs can induce cellular protective mechanism(s) under mild
oxidative stress conditions and if longer exposure of cells to DHPs can potentiate possible effects. To do
so, cells were treated with the selected DHPs for 24-h which were removed from the medium prior to
exposure to stressors (1-h treatment). Hydrogen peroxide and tert-butyl hydroperoxide (tBHP) were
used for induction of mild oxidative stress. In addition to the evaluation of cell growth, measurements
of ROS generation along with intracellular glutathione content were carried out with the latter (tBHP)
since it is known as more stable oxidative stress-inducing agent than hydrogen peroxide that provides
more consistent effects [50]. Notably, for HepG2 cells tBHP, but not hydrogen peroxide, was found
to be able to decrease reduced glutathione as wells as to increase malondialdehyde (MDA) levels
and activity of antioxidative enzymes [50]. Moreover, tBHP was shown to induce caspase-dependent
apoptosis in endothelial cells, which was mediated by ROS generation deriving from NADPH oxidase
and mitochondria [51]. However, we should also stress the fact that hydrogen peroxide in very
important natural ROS with multiple positive and negative bioactivities.
Both used stressors decreased cell growth, thus creating mild oxidative stress, while AV-153 IV-1,
AV-154-Na IV-5, J-9-133-2 II-2, Carbatone II-1, and Diethone I (at low concentration) ameliorated
negative effects of hydrogen peroxide, by promoting cell growth and acting as antioxidants.
The more in-depth analysis of the selected DHPs, considering the influence on cell growth, ROS
production and glutathione content, was carried out with tBHP, known to be more stable and consistent
in induction of oxidative stress, unlike hydrogen peroxide, which has multiple biological activities
and is rapidly metabolized as natural ROS. Glutathione is one of the most important intracellular
antioxidants able to scavenge ROS thus becoming oxidized. The increase in ratio oxidized/reduced
glutathione indicates severity of oxidative stress. tBHP is known to increase this ratio thus causing
depletion of reduced glutathione [50]. We measured total glutathione content (oxidized + reduced)
which should be influenced only by de novo synthesis. tBHP decreased glutathione content, also
observed in Rat clone-9 hepatocytes [52] which could be due to attenuated activation of the GCLc
(glutamate cysteine ligase, catalytic subunit) promoter [53], resulting in reduced biosynthesis.
The selected DHPs were able to amend tBHP-induced glutathione depletions at least in some
of the tested concentrations. Such effect was observed in rats exposed to benzo(a)pyrene-induced
oxidative stress, where pre-treatment with Nitrendipine increased the glutathione but also superoxide
dismutase (SOD) levels while decreasing TBARS levels [54].
Moreover, AV-154-Na IV-5 (1000 µM), E2-134-1 III-4 (500 µM), Diethone I (100 µM), Carbatone
II-1 (250 µM), E3-46 IV-3 (250 µM), and Thiocarbatone III-1 (100 µM and 500 µM) were able to induce
glutathione biosynthesis. Indeed, the concentration-dependent diversity in patterns of intracellular
glutathione and of ROS levels was observed in our study. Yet, Thiocarbatone III-1, Carbatone II-1 and
in particular E2-134-1 III-4 were the only DHPs able to promote cell growth under such mild oxidative
stress conditions acting in a concentration dependent manner. While growth promotion was related
to the reduction of ROS and the induction of intracellular glutathione for E2-134-1 III-4 (250 µM and
500 µM) and Carbatone II-1 (250 µM), with the strongest observed increase of glutathione, the increase
of intracellular ROS was also noticed for Thiocarbatone III-1 (100 µM).The major pathway activated
upon stress conditions is NRF2/KEAP1 [55]. NRF2 activates genes that encode phase II detoxifying
enzymes and antioxidant enzymes thus influencing glutathione content. Recently, DHPs (Nifedipine
and Amlodipine) were shown to activate NRF2 via a phosphoinositide 3-kinase (PI3K)-dependent
mechanism [56]. At this point, we cannot fully explain observed concentration-dependent diversities
in ROS and glutathione content, being sometimes reversal as expected, and the others not, or can we
explain lack of linearity. However, we can assume that the onset of lipid peroxidation, generating
reactive aldehydes, especially 4-hydronynoenal known to act as a second messenger of free radicals and
signaling molecules regulating cell growth and inducing endogenous production of ROS, eventually
affecting the activity and synthesis of glutathione might be, at least in part, responsible for that [57–59].
Interestingly, these DHPs did not affect cell growth, unlike growth-supporting DHPs E2-134-1 III-4
and Carbatone II-1, which were found to increase glutathione and reduce ROS production, thus acting
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as potent antioxidants. On the other hand, Thiocarbatone III-1 could not decrease ROS although it
enhanced the growth of the HOS cells. These findings again suggest involvement of other survival
pathway(s) that might include second messengers of free radicals, which are since recently also in
focus of research as growth regulators [60–62]. In favor of this possibility are also pro-oxidative effects
of Thiocarbatone III-1, resembling similar effects of HNE, while the other DHPs were also acting as
pro-oxidants at certain concentration.
This dual phenomenon is characteristic also for some other compounds (e.g., ascorbic acid), acting
either as antioxidants or as pro-oxidants, depending on given conditions [63]. For alpha-tocopherol
(vitamin E) and even for polyphenols and thiols, the persistent rhetoric question is if vitamin E
should be considered as a pro- or an anti-oxidant [64,65]. This question is actual similar for DHPs,
in the case of which the likely answer could be both antioxidants and/or pro-oxidants, depending
on the compound’s individual structure determinants, like C. Winterburn stated: “Antioxidants are
individuals” [65]. The same appears to be valid for bioactive DHP antioxidants, too.
DHPs, such as Thiocarbatone III-1, E2-134-1 III-4, Carbatone II-1, AV-153 IV-1, AV-154-Na IV-5,
J-9-133-2 II-2, and Diethone I were able to attenuate negative effects of oxidative stress in human
osteoblast-like cells. Their action was highly dependent on the concentration used, stressor applied and
treatment set-up. Thus, the observed growth-supporting effects suggest that they might be eventually
considered as promising therapeutic agents in the treatment of osteoporosis as was observed for
Cilnidipine [66] and Amlodipine [67] in murine translation models.
5. Conclusions
Eleven out of the 28 structurally different compounds tested (27 DHP derivatives and one
oxidized form pyridine-type heteroaromatic compound), in particular, Diethone I, AV-154-Na IV-5,
Thiocarbatone III-1, E2-134-1 III-4, E2-136-2 III-6, J-9-133-2 II-2, E3-46 IV-3, J-11-71-2 IV-7, V-6-55-1
IV-4, Carbatone II-1 and AV-153 IV-1 were about 10-fold more effective antioxidants than uric acid
and were further tested in the HOS model of human osteoblast-like cells. From the selected DHPs,
Thiocarbatone III-1, E2-134-1 III-4, Carbatone II-1, AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2, and
Diethone I were able to attenuate negative effects of oxidative stress in human osteoblast-like cells
induced by pro-oxidants. These bioactive DHP antioxidants acted in a concentration-dependent
manner, while their efficiency was also related to the pro-oxidant stressor applied and experimental
treatment set-up. Thiocarbatone III-1, Carbatone II-1 and E2-134-1 III-4 were found to be undoubtedly
the most potent compounds with growth-promoting effects and the only DHPs being able to act so in
tBHP-induced oxidative stress conditions. The observed induction of de novo glutathione synthesis by
HOS cells, observed upon treatment with these DHPs, implicates involvement of the NRF2 signaling
pathway. While Carbatone II-1 and E2-134-1 III-4 have shown concordant reduction in ROS, for
Thiocarbatone III-1, increased ROS contributing to cell growth suggested other survival mechanism(s)
involved. Surprisingly, Diethone I (known antioxidant) did not affect cell growth even though it
decreased ROS and mostly resulted in increasing glutathione in such conditions. Likewise, Diethone I
and AV-153 IV-1 were more protective if hydrogen peroxide was used as a stressor. In addition, AV-153
IV-1 appeared to be more effective if directly acting as a scavenger of hydrogen-peroxide for shorter
time, like Diethone I, while Thiocarbatone III-1 and E2-134-1 III-4 acted seemingly both as scavengers
of ROS and as inducers of growth promoting signaling pathways. Therefore, we assume that HNE and
related second messengers of free radicals generated by lipid peroxidation might be relevant factors
for the bioactivity principles of bioactive DHPs, which should be further studied.
Finally, the results of our study together with supporting evidence for other DHPs [66,67] as
well as with other antioxidants [17], suggest that DHPs could be considered as therapeutic agents for
osteoporosis although further research is needed to elucidate mechanisms involved.
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DHP(s) 1,4-dihydropyridine(s)
OS oxidative stress
AO Antioxidant
AOA antioxidative activity
TAC total antioxidative capacity
TOC total oxidative capacity
ROS reactive oxygen species
HRP horse radish peroxidase
TMB 3,3′,5,5′-tetramethylbenzydine
DCFH-DA 2′,7′-dichlorodihydrofluorescein diacetate
tBHP tert-butyl hydroperoxide
BrdU 5-bromo-2′-deoxyuridine
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